Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

IL-6 signaling blockade can alleviate severe COVID-19

A team of researchers led by Osaka University find an overlap in the pathogenesis of cytokine release syndrome and COVID-19, and show that the symptoms of both can be alleviated by IL-6 signaling blockade

31 Aug 2020

New lipid derivatives of Remdesivir have higher anti-coronavirus activity

In a fascinating new preprint paper published on bioRxiv* in August 2020, the researchers report “the synthesis and antiviral evaluation of three novel lipophilic prodrugs of RVn-monophosphate that are substantially more active than Remdesivir in cells infected with SARS-CoV-2.” These could be of immense use in treating COVID-19 patients early and helping to end transmission.

30 Aug 2020

Using SARS-CoV-2 epitope to construct a vaccine

A new study published on the preprint server bioRxiv* in August 2020 reports the use of prediction and advanced simulation techniques to identify a novel T cell epitope on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as the basis for a customized vaccine with broad-based efficacy.

30 Aug 2020

SARS-CoV-2 Neucleocapside (N) protein is heavily glycosylated

However, the nucleocapsid (N) protein is also extremely abundant and, therefore, a useful target for both vaccine and diagnostic test development. A new study published on the preprint server bioRxiv in August 2020 reveals the structure of this protein, a valuable step in using it for these purposes.

30 Aug 2020

Severe and fatal COVID-19 is rare in children

Now, a new study by researchers at the Universities of Edinburgh and Liverpool, Imperial College London, and the Royal Hospital for Children, Glasgow in the United Kingdom has shown that children and teenagers are less likely than adults to develop severe COVID-19 or die from the disease.

30 Aug 2020

Scientists describe known approaches for treatment of SARS-CoV-2 infection

Researchers from Sechenov University together with Russian and Iranian colleagues described currently known approaches to the treatment of SARS-CoV-2 infection.

29 Aug 2020

Researchers develop advanced imaging technique to visualize effects of valencies on B cell responses

Designing a vaccine starts with finding the right ingredients. Every infectious agent has molecules, called antigens, that the immune system could potentially recognize and attack. So scientists must carefully consider which antigens should go into a vaccine.

28 Aug 2020

FDA continues to take action in the ongoing response to COVID-19 pandemic

The U.S. Food and Drug Administration (FDA) today continued to take action in the ongoing response to the COVID-19 pandemic

28 Aug 2020

Researchers discover how brain cancer cells evade the body's immune system

Researchers in China have discovered how brain cancer cells increase production of a key protein that allows them to evade the body's immune system.

27 Aug 2020

Study shows furin cleavage site is crucial for SARS-CoV-2 replication

In a recent bioRxiv* preprint paper, researchers from the United States demonstrate the pivotal role the furin cleavage site insertion in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein plays in viral replication and pathogenesis – highlighting, in turn, the need for mutation monitoring when developing therapeutics and vaccines.

27 Aug 2020

Dotmatics announces the launch of Bioregister 2020.1

Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced the introduction of Bioregister 2020.1, the latest version of its web-based application for registering sequence-based, chemically modified and structure-less biological entities.

27 Aug 2020

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

The COVID-19 pandemic is still creating economic and health-related impact over the world. A new study published on the preprint server bioRxiv in August 2020 shows that a gp96-Ig-secreting vaccine candidate based on the expression of full-length spike protein generates a potent T cell response.

26 Aug 2020

Study suggests memory B cells persist following COVID-19 recovery

Researchers at Tel Aviv University in Israel have gained valuable insights into the serological and B cell response to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

26 Aug 2020

BM32 vaccine against grass pollen allergy could be potential treatment for hepatitis B infection

Chronic hepatitis B infections represent a global health problem that could hitherto only be treated by chemotherapy.

26 Aug 2020

Synthetic gene fragments from SARS-CoV-2 can help produce accurate diagnostic tests

Researchers at the National Institute of Standards and Technology (NIST) have produced synthetic gene fragments from SARS-CoV-2, the virus that causes COVID-19. This material, which is non-infectious and safe to handle, can help manufacturers produce more accurate and reliable diagnostic tests for the disease.

26 Aug 2020

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.

25 Aug 2020

Preclinical studies of a COVID-19 vaccine candidate show positive results

Preclinical studies of a COVID-19 vaccine candidate at the University of Alabama at Birmingham show positive results that appear to distinguish this vaccine candidate from other vaccine candidates that are currently in advanced stages of clinical development, the Maryland-based Altimmune Inc. announced today.

25 Aug 2020